Home › Compare › INPOY vs ABBV
INPOY yields 23.11% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 10
Combined, INPOY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of INPOY + ABBV for your $10,000?
InPost S.A., together with its subsidiaries, operates as an out-of-home e-commerce enablement platform providing parcel locker services in Europe. It operates through four segments: APM (automated parcel machines), To-Door, Mondial Relay, and International Other. The APM segment focuses on the delivery of parcels to automated parcel machines. The To-Door segment delivers parcels using door-to-door couriers. The Mondial Relay segment delivers parcels to automated parcel machines; and operates pick-up drop-off (PUDO) points in France, Spain, Belgium, Netherlands, and Portugal. The International Other segment delivers parcels to automated parcel machines in the United Kingdom and Italy. The company also provides fulfilment services, including comprehensive warehousing, packaging, and logistics services to e-commerce merchants; operates self-service parcel dispatch and collection points; and e-Grocery, a delivery service for food and FMCG products through InPost Fresh app to dedicated machines and to the recipient. As of December 31, 2021, it handled 517 million parcel deliveries, and installed approximately 2.4 million lockers across its network of 16,445 APMs. The company also had approximately 38,000 integrated merchants and 8 million active mobile users on its mobile application. InPost S.A. was founded in 1999 and is based in Luxembourg, Luxembourg.
Full INPOY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.